In a murine model of NSCLC, Cascone et al. demonstrated that neoadjuvant anti-PD-1, anti-CTLA-4, or combination ICI followed by resection 2 days after therapy resulted in improved survival compared to adjuvant therapy. Here, CTLA4 is linked to non-small cell lung carcinoma.